33 results about "Lutenizing hormone" patented technology

A compound is provided that has the formula

NH₂CH₂CH₂CH₂C(O)N—R   (I)

where R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidetransferrin, glucosylamnine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

There are provided a fused pyrimidine compound having antagonistic activity against luteinizing hormone releasing hormone, and a medicine containing the compound. A luteinizing hormone releasing hormone antagonist containing a compound represented by the formula:

wherein R^1a is a hydrocarbon group which may be substituted or a hydrogen atom,

• • ring A^a is a 6-membered aromatic ring which may be further substituted,
  • ring B^a is a homocyclic or heterocyclic ring which may be further substituted,
  • W^a is an oxygen atom or a sulfur atom,
  • X^a1 and X^a2, which may be identical or different, are each a hydrogen atom, a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted, or X^a1 and X^a2 together may form an oxygen atom, a sulfur atom or NR^3a (wherein R^3a is a hydrocarbon group which may be substituted or a hydrogen atom), and
  • Y^a is C_1-6 alkylene which may be substituted or a bond, or a salt or prodrug thereof.

The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

The present invention relates to a composite microsphere system comprising poly(D,L-lactide-co-glycolide) (PLGA), poly(acryloyl hydroxyethyl starch) (AcHES), and a pharmaceutically effective amount of a biologically active compound. The active compound may be, for example, an insulin, an interferon, a luteinizing hormone-releasing hormone (LHRH) analog, a somatostatin and/or derivatives thereof, a calicitonin, a parathyroid hormone (PTH), a bone morphogenic protein (BMP), an erythropoietin (EPO), an epidermal growth factor (EGF) or a growth hormone. This invention also relates to methods of using the composite microspheres, and methods of preparing same.

The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

One aspect of the present invention is concerned with a method of controlled ovarian hyperstimulation in a mammalian female, said method comprising the co-administration to said female of a substance having follicle stimulating hormone activity (FSH substance) in an amount effective to stimulate multiple follicular development;—gonadotropin releasing hormone (GnRH) antagonist in an amount equivalent to a daily subcutaneous dose of at least 0.5 mg ganirelix to prevent a premature LH-surge; and—a LH substance in an amount effective to prevent or suppress symptoms of luteinising hormone (LH) deficiency resulting from the administration of the GnRH antagonist; followed by administering a meiosis and luteinisation inducing substance (ML substance) in an amount effective to stimulate resumption of meiosis and luteinisation, and wherein the LH substance is not obtained from the urine of human females. Another aspect of the to invention relates to a pharmaceutical kit for use in a method of controlled hyperstimulation, which kit comprises:—at least one parenteral or oral dosage unit containing one or more FSH substances in an amount equivalent to a subcutaneous dose of 50-1500 I.U. FSH;—at least one parenteral dosage unit containing one or more GnRH antagonists in an amount equivalent to a subcutaneous dose of 0.5-25 mg ganirelix;—at least one parenteral dosage unit containing one or more LH substances in an amount equivalent to a subcutaneous dose of 50-3000 I.U. recombinant LH; wherein the LH substance is not obtained from the urine of human females.

The invention discloses an ovary vitrification cryopreservation method under intervention of luteinizing hormone. The ovary vitrification cryopreservation method comprises the following steps: soaking an in-vitro ovary into a culture solution, putting into a constant-temperature incubator with 5 percent of CO2 at the temperature of 37 DEG C for culture, then transferring into a permeable cryoprotective agent-containing ethylene glycol pre-equilibrium solution for soaking, after then, transferring into a high-concentration cryoprotective agent-containing vitrified cryopreservation fluid for continuous permeable equilibrium, and finally transferring into liquid nitrogen for soaking for at least 24 hours. A thawing process comprises the steps of taking out the cryopreserved ovary from the liquid nitrogen, placing the ovary into 0.50 mol/L, 0.25 mol/L and 0.125 mol/L of thawing solutions which are preheated at the temperature of 37 DEG C and has the sucrose concentration gradually decreased in sequence for 10 min, then transferring the ovary into the culture solution, and putting into the constant-temperature incubator with 5 percent of CO2 at the temperature of 37 DEG C for culture; the culture solution, the pre-equilibrium solution, the vitrified cryopreservation fluid and the thawing solution contain the luteinizing hormone, so that the survival rate of the cryopreserved ovary can be increased, and the reproductive function and the endocrine function can be retained to a relatively large extent.

The invention relates to application of clomifene citrate to anti-mycobacterium tuberculosis medicines. Clomifene citrate has estrogenic and antiestrogenic properties that appear to prevent the release of gonadotropins, follicle-stimulating hormone and luteinizing hormone, thus leading to follicular development and maturation, ovulation and subsequent corpus luteum development and function and then resulting in pregnancy. It is found through researches that the clomifene citrate has an antitubercular effect and has good development value. The application of the clomifene citrate to anti-mycobacterium tuberculosis medicines and the obvious anti-mycobacterium tuberculosis effect of the clomifene citrate are disclosed for the first time.

Disclosed are compounds of the formula (I) wherein R is C₁-C₃₀ alkyl, which may be optionally further substituted with one or more C₅-C₈ cycloalkyl groups, or a C₅-C₁₂ cycloalkyl, which may be optionally substituted with one or more C₁-C₃₀ alkyl groups, R′ is hydrogen or lower alkyl, R″ is a C₁-C₃₀ alkyl or halo, and the bond between C14 and C15 can be a single bond or double bond. Also disclosed are pharmaceutical compositions comprising such compounds and methods of use thereof. These compounds can find use in treating a number of diseases or conditions such as hypogonadism, hypergonadism, osteoporosis, and anemia, in providing hormonal therapy and contraception, as an anabolic agent, and in suppressing the release of hormones such as the luteinizing hormone.

Disclosed herein are devices, systems, methods and kits for performing immunoassay tests to detect for at least progesterone or analytes of progesterone on a sample in association with diagnosing problems and issues associated with corpus luteum functionality. The immunoassay devices and methods may be used in conjunction with diagnostic reader systems and/or a base unit for obtaining a sensitive readout of the immunoassay results. The methods disclosed herein may also incorporate steps associated with evaluating the urine of a sample for the presence of an estrogen metabolite and/or luteinizing hormone.

A method for the treatment of advanced prostate cancer comprises administering to a patient suffering from advanced prostate cancer an androgen suppressing amount of a luteinizing hormone releasing hormone agonist analog and an amount of calcitriol sufficient to enhance the effectiveness of the luteinizing hormone releasing hormone agonist analog against the cancer relative to treatment with the luteinizing hormone releasing hormone agonist analog alone. Preferably the calcitriol is in the form of a stabilized, injectable solution of calcitriol in isotonic saline containing about 1 to about 30 milligrams per milliliter of calcitriol and a sufficient quantity of nonionic surfactant to solubilize the calcitriol therein. Preferably the a luteinizing hormone releasing hormone agonist analog is a nonapeptide or decapeptide agonist, such as leuprolide, goserelin or salts thereof. The method of the present invention affords a surprisingly improved efficacy for treatment of advanced prostate cancer such as androgen-independent prostate cancer (AIPC) or hormone refractory prostate cancer (HRPC) in comparison to treatment with a luteinizing hormone releasing hormone agonist analog alone.

Disclosed is a method for producing hybrid or non-hybrid recombinant glycoprotein hormones, for example the recombinant equine chorionic gonadotropin (r-eCG), the hybrid recombinant chorionic gonadotropin, the recombinant thyroid-stimulating hormone (r-TSH), the recombinant luteinising hormone (r-LH), the luteinising hormone and the recombinant follicle-stimulating hormone (r-FSH). In addition, the present invention relates to the recombinant glycoprotein hormones comprising the equine α and β subunits, inter alia, the α subunit of mammals and equine β subunit, where the two subunits are fused in a simple chain, and chain-modifying agents, which hormones are easier to purify, more homogeneous, easier to produce on an industrial scale without using animals, in comparison with the wild glycoprotein hormone The hormones are useful for inducing animal reproduction, ovulation induction, superovulation induction, follicle growth, oestrus induction, anoestrus reversal, puberty induction in animals, both with and without commercial interest.

The present invention is directed to a new kind of medicinal value or health care function of Eurycoma longifolia extracts, particularly in the treatment or alleviation symptoms and/or conditions associated to hormonal imbalance in females, including menopause and its related symptoms. In one aspect, the present invention discloses the use of a composition comprising a therapeutically effective amount of Eurycoma longifolia extract in the manufacture of a medicament for the alleviation of symptoms and/or conditions associated to hormonal imbalance in females, including menopause and its related symptoms. The alleviation of the symptoms and/or conditions according to the present invention is characterised by inducing a change in the hormonal contents of estrogen, progesterone, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Also disclosed is the use of a pharmaceutical composition comprising the therapeutically effective amount of Eurycoma longifolia extract.

Disclosed are 3',3'-N-bisdesmethyl-3',3'-N-bis-substituted-6-O-methyl-11-deoxy-11,12 -cyclic carbamate erythromycin A derivatives of formula (I) which are antagonists of lutenizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, methods of using the compounds and the process of making the same.

The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.